AEMD:NSD-Aethlon Medical, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 1.35

Change

-0.08 (-5.59)%

Market Cap

USD 0.02B

Volume

0.29M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-30 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

+7.19 (+2.25%)

USD25.23B 14.49 68.43
PODD Insulet Corporation

+4.62 (+1.99%)

USD15.23B 773.39 143.86
LVGO Livongo Health, Inc

+1.60 (+1.16%)

USD13.96B N/A N/A
ABMD Abiomed, Inc

+4.60 (+1.69%)

USD12.27B 75.42 46.69
TNDM Tandem Diabetes Care, Inc

+0.89 (+0.79%)

USD6.86B N/A N/A
BRKR Bruker Corporation

-0.15 (-0.38%)

USD6.12B 36.51 18.69
SDC SmileDirectClub, Inc

+0.07 (+0.60%)

USD4.45B N/A N/A
WMGI Wright Medical Group N.V

-0.04 (-0.13%)

USD3.97B N/A 62.99
IART Integra LifeSciences Holdings ..

+0.80 (+1.72%)

USD3.91B 160.06 27.46
SWAV ShockWave Medical, Inc

+1.29 (+1.73%)

USD2.53B N/A N/A

ETFs Containing AEMD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 40.63% 78% C+ 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.63% 78% C+ 83% B
Trailing 12 Months  
Capital Gain 462.50% 99% A+ 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 462.50% 99% A+ 97% A+
Trailing 5 Years  
Capital Gain -80.52% 29% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -80.52% 27% F 9% F
Average Annual (5 Year Horizon)  
Capital Gain 20.84% N/A N/A 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.84% N/A N/A 78% C+
Risk Return Profile  
Volatility (Standard Deviation) 155.86% N/A N/A 5% F
Risk Adjusted Return 13.37% N/A N/A 41% F
Market Capitalization 0.02B 10% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.05 92% A- 71% C-
Price / Cash Flow Ratio -3.32 52% F 70% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -70.64% 37% F 18% F
Return on Invested Capital -92.68% 24% F 10% F
Return on Assets -37.28% 23% F 9% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.87 72% C- 65% D
Short Percent 3.71% 60% D- 47% F
Beta 0.35 84% B 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector